Treatment of advanced non-small cell lung cancer: chemotherapy with or without cisplatin?

Gebbia, Vittorio; Oniga, Francesco; Agueli, R.; Paccagnella, Adriano

doi:10.1093/annonc/mdj933

Cited by 9 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, quite recently the use of non-platinum regimens, often taxane-based ones, has become more frequent due to the oncologists' desire of avoiding the difficulties linked to cisplatin use and to ameliorate tolerability [30] . This attitude has recently been attenuated by the results of large trials that have failed to show superiority or better tolerability of such regimens over the platinum-based ones in fit patients, while a possible role still exists in elderly and/or patients with a performance status of 2.…”

Section: Drugs Employedmentioning

confidence: 99%

Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?

Gebbia

2008

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Background : A growing percentage of patients affected by advanced non-small cell lung cancer who progressed after first-line chemotherapy still have a good performance status and require second-line treatment.Objective : An overview of the state of the art of second-line therapeutic options is presented. Methods : The scope of the review is to give an update on the therapeutic options currently available for the second-line treatment of patients with advanced non-small cell lung cancer. Results and conclusions : Among chemotherapeutic drugs docetaxel and pemetrexed have been approved for second-line treatment of advanced non-small cell lung cancer. Although the drugs are equiactive in terms of response rate and survival parameters the latter has a clear-cut advantage in terms of tolerability and quality of life. Therefore, pemetrexed is considered the best second-line therapeutic option in order to avoid severe side effects. Among biologic agents the tyrosine kinase inhibitors gefinitib and erlotinib have been largely tested, but only the latter has been approved for second-and third-line treatment. Erlotinib has been reported to be particularly active in patients with adenocarcinoma, in females, in patients of Asian ethnicity and in epidermal growth factor receptor mutations and it is also active in the third-line setting. At present, no direct head to head comparison of erlotinib with any chemotherapeutic agent has been performed. A rational decision tree may therefore include pemetrexed or docetaxel (the former preferred for tolerability) or erlotinib as standard second-line therapy. Erlotinib has been also shown to be active as third-line treatment: however, in cases of patients with clinical characteristics suggesting a good response to tyrosine kinase inhibitors, erlotinib may be employed in an earlier phase.

show abstract

Section: Drugs Employedmentioning

confidence: 99%

Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?

Gebbia

2008

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases. Though the early treatment approaches for NSCLC are surgery, chemotherapy, immunotherapy, or radiation, all of which are efficacious for treating the earlier stages of the disease, treating the later stages remains challenging [ 2 , 3 ]. Cancer cells possess oncogenic features that result in genomic abnormalities leading to production and degradation of proteins in an imbalanced manner.…”

Section: Introductionmentioning

confidence: 99%

The NRF2-p97-NRF2 negative feedback loop

et al. 2023

View full text Add to dashboard Cite

“…Although NSCLC is one of the most challenging cancers to treat, several previous clinical trials have demonstrated that systemic combination chemotherapy with platinum-based agents has advantages in prolonging survival and improving quality of life in NSCLC patients [6]. Cisplatin is the first platinum-based anti-cancer drug introduced to clinical treatment, and plays a central role in therapy for NSCLC.…”

Section: Introductionmentioning

confidence: 99%

NBM-T-BMX-OS01, an Osthole Derivative, Sensitizes Human Lung Cancer A549 Cells to Cisplatin through AMPK-Dependent Inhibition of ERK and Akt Pathway

Chen

Zhou

Ning

et al. 2015

Cell Physiol Biochem

View full text Add to dashboard Cite

Background: Drug combination therapies using cisplatin and natural products are common practice in the treatment of human lung cancer. Osthole is a natural compound extracted from a number of medicinal plants and has been shown to exert strong anticancer activities with low toxicity. Methods: In the present study, NBM-T-BMX-OS01 (BMX), derived from the semi-synthesis of osthole, was evaluated in cisplatin treated A549 cells to investigate its effect on cisplatin resistance in human lung cancer. The anticancer effect of BMX were measured by cell viablity‚ colony formation‚ TUNEL staining‚ flow cytometry and cell cycle assay. The fluorescence staining was performed to detect intracellular and mitochondrial reactive oxygen species (ROS) generation. Western blot analysis, antagonists pretreatment and small interfering RNA (siRNA) transfection were used to determine the potential mechanism. Results: It was found that, in comparison with single cisplatin treatment, the combination of BMX and cisplatin resulted in greater efficacy in inhibition of proliferation and colony formation, apoptosis induction and cell cycle arrest. The results of fluorescence staining showed that the combination effect of BMX and cisplatin was due to oxidative stress induced by mitochondrial ROS generation. In addition, BMX significantly attenuated the phosphorylation of ERK and Akt, two important pro-survival kinases. In contrast, BMX inhibited the activation of AMPK, and knockdown of AMPK using specific siRNA partially reversed BMX-induced inhibition of ERK and Akt, as well as its synthetic effects on cisplatin induced anticancer activity in A549 cells. Conclusion: Taken together, this study provides that BMX might modulate cisplatin resistance through AMPK-ERK and AMPK-Akt pathways. These results also support the role of BMX as a potential drug candidate for use in combination with cisplatin in the treatment of human lung cancer.

show abstract

Treatment of advanced non-small cell lung cancer: chemotherapy with or without cisplatin?

Cited by 9 publications

References 34 publications

Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?

Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?

The NRF2-p97-NRF2 negative feedback loop

NBM-T-BMX-OS01, an Osthole Derivative, Sensitizes Human Lung Cancer A549 Cells to Cisplatin through AMPK-Dependent Inhibition of ERK and Akt Pathway

Contact Info

Product

Resources

About